Daniel S. Kim

Dan is a founding member of Orrick's Santa Monica Office and a partner in Orrick’s Technology Companies Group where he advises disruptive technology companies at all stages of their life cycles.

• Engagements

  VENTURE CAPITAL FINANCINGS

  • Represented Luminar Technologies in its $250 million worth of venture capital financings and $184 Series X Preferred Stock financing
  • Represented Pinterest in its $150 million Series H Preferred Stock financing
  • Represented a developer of therapeutics for acute and chronic cardiovascular, and autoimmune and inflammatory diseases in its $60 million Series C Preferred Stock financing
  • Represented the lead investor in the $96 million Series D-2 Preferred Stock financing of a leading cloud provider of tax compliance automation for businesses of all sizes
  • Represented a strategic investor in the $73.5 million Series E Preferred Stock financing of a fuel-cell manufacturer
  • Represented the lead investor in a $52 million Series D Preferred Stock financing of a renewable oil and bioproducts company
  • Represented a specialty pharmaceutical company in its $45 million Series C Preferred Stock financing
  • Represented a provider of mobile marketing solutions in its $22 million Series E Preferred Stock financing
  • Represented a women’s healthcare company in its $15 million Series C Preferred Stock financing
  • Represented a data analytics company in its $15 million Series A-1 and Series A-2 Preferred Stock financing
  • Represented a provider of biological software in its $15 million Series E Preferred stock financing
  • Represented the lead investor in the $15 million Series C Preferred Stock financing of an advertising technology company
  • Represented a provider of converged cloud storage and application optimization products in its $12 million Series B Preferred Stock financing
  • Represented the lead investor in the $6.5 million Series C Preferred Stock financing of a manufacturer of devices designed to optimize rapid perfusion and clot removal in the treatment of patients suffering from ischemic stroke
  • Represented a provider of imaging solutions for the home furnishings industry in its $6.5 million Series A Preferred Stock financing
  • Represented the lead investor in the $5 million Series B Preferred Stock financing of a SaaS wellness company
  • Represented the lead investor in the $5 million Series A Preferred Stock financing of a producer of advanced cell separation tools and accessories to support regenerative medicine workflows
  • Represented dozens of other technology companies, venture capital firms, strategic investors, and angel investors in various preferred stock financings, convertible note financings and other private company capital-raising transactions.

  MERGERS & ACQUISITIONS

  • Represented Luminar Technologies in its $3.4 billion SPAC merger with Gores Metropoulos
  • Represented Momentus in its $1.2 billion SPAC merger with Stable Road Acquisition Corp
  • Represented Planet Labs in its acquisition of Terra Bella Technologies from Google
  • Represented Yes in its sale to Twitter
  • Represented a publicly-traded, commercial-stage biotechnology company in its acquisition of a biopharmaceutical company for $45 million in cash and stock, and future earn-outs of up to $195 million
  • Represented Ceradyne in its sale to 3M Company for $860 million in an all-cash tender offer
  • Represented Compellent Technologies in its sale to Dell for $940 million
  • Represented ZestFinance in its joint venture with JD.com in China
  • Represented a managed services provider in its carve-out acquisition of the managed IT services division of a full-lifecycle spatial systems integrator
  • Represented a leading designer of mobile device accessories in its acquisition of an emerging mobile device accessories company
  • Represented a premier supplier of advanced technology products for the ruggedized electronics military market in its sale to a publicly traded, global manufacturer of aircraft products
  • Represented and successfully defended Qualstar Corporation against a hostile tender offer and defeated an activist shareholder in a proxy contest
  • Represented a private equity firm in its acquisition of a nationally branded dental laboratory and in its three follow-on acquisitions of leading dental laboratories
  • Represented a private equity firm in its acquisition of a platform chiropractic software company and in its follow-on acquisition of a leading chiropractic software company
  • Represented a portfolio company of a private equity firm in its strategic acquisition of a provider of contact center solutions and managed services
  • Represented a private equity firm in its acquisition of an independent provider of innovative communications solutions
  • Represented Cortex Pharmaceuticals in its acquisition by merger of Pier Pharmaceuticals
  • Represented a venture capital firm in its acquisition of the assets of a biopharmaceutical company in an assignment for the benefit of creditors proceeding, and in its subsequent sale of such assets to a clinical-stage, publicly traded biopharmaceutical company
  • Represented a publicly traded leader in high performance computing in its acquisition of a Japanese sales and service organization
  • Represented various other companies and institutional investors in buy-side and sell-side engagements, involving both public and private company targets and acquirers

  PUBLIC OFFERINGS & PIPEs

  • Represented Luminar Technologies in its going public de-SPAC transaction with Gores Metropoulos
  • Represent Momentus in its going public de-SPAC transaction with Stable Road Acquisition Corp.
  • Represented Beyond Meat in its initial public offering
  • Represented Silvair in its initial public offering on the Warsaw Stock Exchange (a case of first impression)
  • Represented First Foundation Inc. in its initial public offering
  • Represented underwriter Goldman, Sachs & Co. in the $98.7 million follow-on offering of InterMune
  • Represented Quark Pharmaceuticals, Inc. in its contemplated initial public offering
  • Represented Pacific Mercantile Bancorp in three secondary offerings of common stock
  • Represented Pacific Mercantile Bancorp in its $11.2 million and $26.3 million PIPE offerings
  • Represented various other issuers in follow-on offerings and PIPE offerings including XenoPort, NovaBay Pharmaceuticals, and Anesiva

   PUBLIC COMPANY REPORTING AND SEC COMPLIANCE

  • Prepared SEC filings and advised on various securities law and corporate governance matters for dozens of publicly traded companies including Anesiva, Avigen, Ceradyne, CKE Restaurants, Cortex Pharmaceuticals, Deckers Outdoor Corporation, EMCORE Corporation, NovaBay Pharmaceuticals, Pacific Mercantile Bancorp, Power Integrations, Qualstar Corporation, Spectrum Pharmaceuticals and XenoPort